INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium
29 Noviembre 2023 - 7:00AM
INmune Bio, Inc. (NASDAQ: INMB) (the
“Company”), a clinical-stage immunology company focused on
developing treatments that harness the patient’s innate immune
system to fight disease, is presenting data on the use of
INB03, a dominant-negative TNF inhibitor of soluble TNF (sTNF) in
the treatment of high-risk MUC4 expressing HER2. Roxana Schillaci,
Ph.D., of Instituto de Biología y Medicina Experimental in Buenos
Aries, Argentina, will present her work at the 46th annual San
Antonio Breast Cancer Symposium, which runs from December 5 to 9.
“This work demonstrates another way that MUC4
expression causes resistance to HER2-targeted immunotherapy in
women with resistant breast cancer," said Dr. Schillaci, who is
also associated with CONICET and is senior author of this work.
“MUC4 expression decreases the uptake of the antibody-drug
conjugate T-DXd. Decreased T-DXd uptake results in less tumor
killing in this tumor model and we suspect it plays an important
role in relapse of disease after treatment with T-DXd.”
The poster, titled, “Blocking
soluble TNF to improve potency of trastuzumab-deruxtecan by
increasing internalization and antitumor innate immune response in
a resistant HER2-positive breast cancer model,” shows that
INB03 improves the potency of T-DXd in a model of immunotherapy
resistant HER2+ breast cancer. INB03 decreases resistance to T-DXd
therapy in three ways. INB03 decreases MUC4 expression on the
surface of the breast cancer cells increasing the ability of the
antibody to bind to the HER2 target on the cancer cell. The
combination of low-dose (1.5mg/kg) T-DXd+INB03 decreases tumor
growth as much as full dose (5mg/kg) T-DXd alone suggesting
increased binding of the immunotoxin to the cancer cell improves
anti-tumor effects. INB03 increases internalization of T-DXd and
converts the immunosuppressive TME into one that is more
tumor-sensitive by polarizing tumor associated macrophages (TAM)
from M2-like to M1-like phenotype with increased expression of
IFNg. The poster concludes that the combination of INB03 may allow
for lower doses of T-DXd to be effective in women with MUC4
expressing HER2+ breast cancer and that addition of INB03 may
improve the response to T-DXd in women with resistant HER2+
disease.
“Response rates in women treated with T-DXd is
high, but relapse is common after a period of time. Identifying and
overcoming resistance mechanisms to trastuzumab-based antibody-drug
conjugates (ADC) will be a key to improving outcomes,” said RJ Tesi
M.D., CEO of INmune Bio. “The body of work performed by Roxana
Schillaci is clinically relevant. Resistance to trastuzumab
immunotherapy can be predicted prospectively based on simple
immunohistochemistry stains detecting tumor expression of MUC4. We
hope that this simple step will allow women to receive a treatment
that subverts a resistance mechanism without waiting for treatment
failure. We further believe that this precision medicine approach
should improve the treatment of women with MUC4 expressing breast
cancers.”
ENHERTU® is a registered trademark of Daiichi
Sankyo Company, Limited.
About INB03
INB03 is a DN-TNF inhibitor that neutralizes
soluble TNF (sTNF) without affecting trans membrane TNF (tmTNF) or
TNF receptors. Compared to currently available non-selective TNF
inhibitors, INB03 preserves the immune response to cancer by
decreasing immunosuppressive cells in the TME including TAM and
MDSC while promoting recruitment of anti-tumor immune cells
including cytolytic CD8+ lymphocytes, NK cells and anti-tumor
macrophages. INB03 has completed an open label dose-escalation
Phase I trial in patients with advanced cancer. In that trial,
INB03 was found to be safe and well tolerated - no dose limiting
toxicity was found. INB03 decreased blood biomarkers of
inflammation in patients with advanced cancer. INMB is planning a
Phase II trial that uses INB03 as part of combination therapy.
About INmune Bio, Inc.
INmune Bio, Inc. is a
publicly traded (NASDAQ: INMB), clinical-stage biotechnology
company focused on developing treatments that target the innate
immune system to fight disease. INmune Bio has two product
platforms that are both in clinical trials: The Dominant-Negative
Tumor Necrosis Factor (DN-TNF) product platform utilizes
dominant-negative technology to selectively neutralize soluble TNF,
a key driver of innate immune dysfunction and a mechanistic driver
of many diseases. DN-TNF product candidates are in clinical trials
to determine if they can treat cancer (INB03™), Mild Alzheimer’s
disease, Mild Cognitive Impairment and treatment-resistant
depression (XPro™). The Natural Killer Cell Priming Platform
includes INKmune™ developed to prime a patient’s NK cells to
eliminate minimal residual disease in patients with cancer. INmune
Bio’s product platforms utilize a precision medicine approach for
the treatment of a wide variety of hematologic and solid tumor
malignancies, and chronic inflammation. To learn more, please
visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is
no assurance that any specific outcome will be achieved. Any
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995. Any statements contained in this press release that do
not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations but are subject
to a number of risks and uncertainties. Actual results and the
timing of certain events and circumstances may differ materially
from those described by the forward-looking statements as a result
of these risks and uncertainties. INB03™, XPro1595, and INKmune™
are still in clinical trials or preparing to start clinical trials
and have not been approved by the US Food and Drug Administration
(FDA) or any regulatory body and there cannot be any assurance that
they will be approved by the FDA or any regulatory body or that any
specific results will be achieved. The factors that could cause
actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the Company’s ability to produce more
drug for clinical trials; the availability of substantial
additional funding for the Company to continue its operations and
to conduct research and development, clinical studies and future
product commercialization; and, the Company’s business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors are
identified and described in more detail in the Company’s filings
with the Securities and Exchange Commission, including the
Company’s Annual Report on Form 10-K, the Company’s Quarterly
Reports on Form 10-Q and the Company’s Current Reports on Form 8-K.
The Company assumes no obligation to update any forward-looking
statements in order to reflect any event or circumstance that may
arise after the date of this release.
INmune Bio Contact:
David Moss, CFO(858) 964-3720info@inmunenbio.com
Investor Contact:Jason Nelson, Core IR(516) 842-9614 x-823
INmune Bio (NASDAQ:INMB)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
INmune Bio (NASDAQ:INMB)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024